Really can't believe they admitted to non-compliance with Listing Rule 3.1. Surely there was another way to phrase the response without that admission. Can't see them getting back on the boards any time soon.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%